Omnipod 5 insulin pump for children with type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study looks at how well the Omnipod 5 insulin pump works for children with type 1 diabetes. It helps the hospital team understand how this automated system affects blood sugar control in everyday life, so they can improve diabetes care for kids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be under 16 years old.
- Your child must have type 1 diabetes.
- Your child must be treated at the Paediatric Diabetes Centre of HUDERF in Belgium.
- Your child must start using the Omnipod 5 insulin pump during the study period (May 2025 to April 2026) as part of their regular care.
- You (and your child, if appropriate) must give written permission to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two versions of the Omnipod insulin pump system to see if the newer Omnipod 6 works better at managing blood sugar than the current Omnipod 5. You'll wear one of these systems for several months and share data about how well it helps control your diabetes.
This study tests a new automated insulin delivery system to help people with type 1 diabetes better manage their blood sugar. It aims to see if the system improves glucose control safely.
This study follows people with type 1 diabetes who are using the Omnipod 5 insulin pump. The goal is to understand how well the system works in everyday life by collecting data from your pump, continuous glucose monitor, and occasional home blood tests over one year.
This study is testing how well the Omnipod 5 insulin pump works in everyday life for people with type 1 diabetes. It's for people who are just starting to use this pump, so doctors can see how it helps manage blood sugar in real-world settings.
This study tests whether starting an automated insulin delivery (AID) system soon after a type 1 diabetes diagnosis helps improve blood sugar control and reduces future health problems. The AID system combines a pump and continuous glucose monitor to automatically adjust insulin.
This study tests a new automated insulin pump system (Omnipod) that adjusts insulin doses on its own throughout the day for people with type 2 diabetes. The goal is to see if it helps keep blood sugar levels more stable while reducing the burden of manual insulin management.
Hear when a new Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.